Influenza virus vaccine - Symvivo
Latest Information Update: 02 Oct 2021
At a glance
- Originator Symvivo
- Class DNA vaccines; Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Influenza virus infections
Most Recent Events
- 05 Jul 2021 Early research in Influenza virus infections (Prevention) in Canada (PO) (Symvivo Corporation pipeline, July 2021)
- 04 Sep 2018 Symvivo receives patent allowance for nucleic acid vectors and their uses in USA
- 12 Feb 2015 Symvivo files for patent protection for nucleic acid vectors and their uses in USA